Loading…

The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity

Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybrid...

Full description

Saved in:
Bibliographic Details
Published in:MedChemComm 2024-01, Vol.15 (1), p.234-253
Main Authors: Singh, Atamjit, Kaur, Kirandeep, Mohana, Pallvi, Singh, Karanvir, Sharma, Aman, Prajapati, Jignesh, Goswami, Dweipayan, Khosla, Neha, Kaur, Uttam, Kaur, Rajanbir, Kaur, Rajinder, Rana, Abhineet, Kour, Sandeep, Ohri, Puja, Arora, Saroj, Chadha, Renu, Singh Bedi, Preet Mohinder
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873
cites cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873
container_end_page 253
container_issue 1
container_start_page 234
container_title MedChemComm
container_volume 15
creator Singh, Atamjit
Kaur, Kirandeep
Mohana, Pallvi
Singh, Karanvir
Sharma, Aman
Prajapati, Jignesh
Goswami, Dweipayan
Khosla, Neha
Kaur, Uttam
Kaur, Rajanbir
Kaur, Rajinder
Rana, Abhineet
Kour, Sandeep
Ohri, Puja
Arora, Saroj
Chadha, Renu
Singh Bedi, Preet Mohinder
description Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound AS8 was the most effective against methicillin-resistant Staphylococcus aureus (MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential. AS8 exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover, AS8 was found to be non-toxic and showed a potent in vivo antibacterial efficacy (90% survival at 10 mg kg −1 ) as well as a modulated immune response in the larva-based ( Galleria mellonella ) model of systemic infections. Overall findings confirmed that AS8 can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections. Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting via CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from in vivo infection.
doi_str_mv 10.1039/d3md00580a
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_38283229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918142116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</originalsourceid><addsrcrecordid>eNpdks1v1DAQxS0EolXphTvIEpcKKcVjN1n7hFYtH5VaIUE5WxPHaVwlcbCdRfvf47BlaXuakeY3z89-JuQ1sFNgQn1oxNAwVkqGz8ghrwQvZCX58wf9ATmO8Y4xxkuAqlQvyYGQXArO1SEZbzpLG7uxvZ8GOybqW5q67eD7wkVMbqTdtg6uiRQjrYPHpoiTNSnMA8UxuRpNssFhT_E2r0f626WOTj4tWgtQXH__saaZchuXtq_Iixb7aI_v6xH5-fnTzfnX4urbl8vz9VVhhBKpgKq20nAjoK3KEhkyBjVYxpCD5apqajBLQVuiYBZWhoFdQdkIobCVK3FEPu50p7kebGOym4C9noIbMGy1R6cfT0bX6Vu_0cAkU6LkWeHkXiH4X7ONSQ8uGtv3OFo_R80VqNUZCFgOe_cEvfNzGPP9FkrCGc_vnqn3O8oEH2Ow7d4NML1EqS_E9cXfKNcZfvvQ_x79F1wG3uyAEM1--v8viD-6kKSL</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918142116</pqid></control><display><type>article</type><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><source>Royal Society of Chemistry</source><creator>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</creator><creatorcontrib>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</creatorcontrib><description>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound AS8 was the most effective against methicillin-resistant Staphylococcus aureus (MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential. AS8 exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover, AS8 was found to be non-toxic and showed a potent in vivo antibacterial efficacy (90% survival at 10 mg kg −1 ) as well as a modulated immune response in the larva-based ( Galleria mellonella ) model of systemic infections. Overall findings confirmed that AS8 can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections. Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting via CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from in vivo infection.</description><identifier>ISSN: 2632-8682</identifier><identifier>ISSN: 2040-2503</identifier><identifier>EISSN: 2632-8682</identifier><identifier>EISSN: 2040-2511</identifier><identifier>DOI: 10.1039/d3md00580a</identifier><identifier>PMID: 38283229</identifier><language>eng</language><publisher>England: Royal Society of Chemistry</publisher><subject>Antibacterial activity ; Antibacterial agents ; Antimicrobial agents ; Biocompatibility ; Biofilms ; Chemistry ; Drug development ; Drug resistance ; Effectiveness ; Hybridization ; Hybrids ; Immune response ; Infectious diseases ; Methicillin ; Molecular docking ; Multidrug resistance ; Pharmacology ; Public health ; Staphylococcus infections ; Thymol ; Triazoles ; Virulence factors</subject><ispartof>MedChemComm, 2024-01, Vol.15 (1), p.234-253</ispartof><rights>This journal is © The Royal Society of Chemistry.</rights><rights>Copyright Royal Society of Chemistry 2024</rights><rights>This journal is © The Royal Society of Chemistry 2024 RSC</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</citedby><cites>FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</cites><orcidid>0000-0003-3828-8110 ; 0000-0001-5439-8032 ; 0000-0001-7474-7068</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38283229$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Kaur, Kirandeep</creatorcontrib><creatorcontrib>Mohana, Pallvi</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Prajapati, Jignesh</creatorcontrib><creatorcontrib>Goswami, Dweipayan</creatorcontrib><creatorcontrib>Khosla, Neha</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Rajanbir</creatorcontrib><creatorcontrib>Kaur, Rajinder</creatorcontrib><creatorcontrib>Rana, Abhineet</creatorcontrib><creatorcontrib>Kour, Sandeep</creatorcontrib><creatorcontrib>Ohri, Puja</creatorcontrib><creatorcontrib>Arora, Saroj</creatorcontrib><creatorcontrib>Chadha, Renu</creatorcontrib><creatorcontrib>Singh Bedi, Preet Mohinder</creatorcontrib><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><title>MedChemComm</title><addtitle>RSC Med Chem</addtitle><description>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound AS8 was the most effective against methicillin-resistant Staphylococcus aureus (MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential. AS8 exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover, AS8 was found to be non-toxic and showed a potent in vivo antibacterial efficacy (90% survival at 10 mg kg −1 ) as well as a modulated immune response in the larva-based ( Galleria mellonella ) model of systemic infections. Overall findings confirmed that AS8 can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections. Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting via CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from in vivo infection.</description><subject>Antibacterial activity</subject><subject>Antibacterial agents</subject><subject>Antimicrobial agents</subject><subject>Biocompatibility</subject><subject>Biofilms</subject><subject>Chemistry</subject><subject>Drug development</subject><subject>Drug resistance</subject><subject>Effectiveness</subject><subject>Hybridization</subject><subject>Hybrids</subject><subject>Immune response</subject><subject>Infectious diseases</subject><subject>Methicillin</subject><subject>Molecular docking</subject><subject>Multidrug resistance</subject><subject>Pharmacology</subject><subject>Public health</subject><subject>Staphylococcus infections</subject><subject>Thymol</subject><subject>Triazoles</subject><subject>Virulence factors</subject><issn>2632-8682</issn><issn>2040-2503</issn><issn>2632-8682</issn><issn>2040-2511</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdks1v1DAQxS0EolXphTvIEpcKKcVjN1n7hFYtH5VaIUE5WxPHaVwlcbCdRfvf47BlaXuakeY3z89-JuQ1sFNgQn1oxNAwVkqGz8ghrwQvZCX58wf9ATmO8Y4xxkuAqlQvyYGQXArO1SEZbzpLG7uxvZ8GOybqW5q67eD7wkVMbqTdtg6uiRQjrYPHpoiTNSnMA8UxuRpNssFhT_E2r0f626WOTj4tWgtQXH__saaZchuXtq_Iixb7aI_v6xH5-fnTzfnX4urbl8vz9VVhhBKpgKq20nAjoK3KEhkyBjVYxpCD5apqajBLQVuiYBZWhoFdQdkIobCVK3FEPu50p7kebGOym4C9noIbMGy1R6cfT0bX6Vu_0cAkU6LkWeHkXiH4X7ONSQ8uGtv3OFo_R80VqNUZCFgOe_cEvfNzGPP9FkrCGc_vnqn3O8oEH2Ow7d4NML1EqS_E9cXfKNcZfvvQ_x79F1wG3uyAEM1--v8viD-6kKSL</recordid><startdate>20240125</startdate><enddate>20240125</enddate><creator>Singh, Atamjit</creator><creator>Kaur, Kirandeep</creator><creator>Mohana, Pallvi</creator><creator>Singh, Karanvir</creator><creator>Sharma, Aman</creator><creator>Prajapati, Jignesh</creator><creator>Goswami, Dweipayan</creator><creator>Khosla, Neha</creator><creator>Kaur, Uttam</creator><creator>Kaur, Rajanbir</creator><creator>Kaur, Rajinder</creator><creator>Rana, Abhineet</creator><creator>Kour, Sandeep</creator><creator>Ohri, Puja</creator><creator>Arora, Saroj</creator><creator>Chadha, Renu</creator><creator>Singh Bedi, Preet Mohinder</creator><general>Royal Society of Chemistry</general><general>RSC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T5</scope><scope>7T7</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3828-8110</orcidid><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid><orcidid>https://orcid.org/0000-0001-7474-7068</orcidid></search><sort><creationdate>20240125</creationdate><title>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</title><author>Singh, Atamjit ; Kaur, Kirandeep ; Mohana, Pallvi ; Singh, Karanvir ; Sharma, Aman ; Prajapati, Jignesh ; Goswami, Dweipayan ; Khosla, Neha ; Kaur, Uttam ; Kaur, Rajanbir ; Kaur, Rajinder ; Rana, Abhineet ; Kour, Sandeep ; Ohri, Puja ; Arora, Saroj ; Chadha, Renu ; Singh Bedi, Preet Mohinder</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Antibacterial activity</topic><topic>Antibacterial agents</topic><topic>Antimicrobial agents</topic><topic>Biocompatibility</topic><topic>Biofilms</topic><topic>Chemistry</topic><topic>Drug development</topic><topic>Drug resistance</topic><topic>Effectiveness</topic><topic>Hybridization</topic><topic>Hybrids</topic><topic>Immune response</topic><topic>Infectious diseases</topic><topic>Methicillin</topic><topic>Molecular docking</topic><topic>Multidrug resistance</topic><topic>Pharmacology</topic><topic>Public health</topic><topic>Staphylococcus infections</topic><topic>Thymol</topic><topic>Triazoles</topic><topic>Virulence factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Kaur, Kirandeep</creatorcontrib><creatorcontrib>Mohana, Pallvi</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Prajapati, Jignesh</creatorcontrib><creatorcontrib>Goswami, Dweipayan</creatorcontrib><creatorcontrib>Khosla, Neha</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Rajanbir</creatorcontrib><creatorcontrib>Kaur, Rajinder</creatorcontrib><creatorcontrib>Rana, Abhineet</creatorcontrib><creatorcontrib>Kour, Sandeep</creatorcontrib><creatorcontrib>Ohri, Puja</creatorcontrib><creatorcontrib>Arora, Saroj</creatorcontrib><creatorcontrib>Chadha, Renu</creatorcontrib><creatorcontrib>Singh Bedi, Preet Mohinder</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MedChemComm</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Atamjit</au><au>Kaur, Kirandeep</au><au>Mohana, Pallvi</au><au>Singh, Karanvir</au><au>Sharma, Aman</au><au>Prajapati, Jignesh</au><au>Goswami, Dweipayan</au><au>Khosla, Neha</au><au>Kaur, Uttam</au><au>Kaur, Rajanbir</au><au>Kaur, Rajinder</au><au>Rana, Abhineet</au><au>Kour, Sandeep</au><au>Ohri, Puja</au><au>Arora, Saroj</au><au>Chadha, Renu</au><au>Singh Bedi, Preet Mohinder</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity</atitle><jtitle>MedChemComm</jtitle><addtitle>RSC Med Chem</addtitle><date>2024-01-25</date><risdate>2024</risdate><volume>15</volume><issue>1</issue><spage>234</spage><epage>253</epage><pages>234-253</pages><issn>2632-8682</issn><issn>2040-2503</issn><eissn>2632-8682</eissn><eissn>2040-2511</eissn><abstract>Bacterial resistance toward available therapeutic agents has become a nightmare for the healthcare system, causing significant mortality as well as prolonged hospitalization, thereby needing the urgent attention of research groups working on antimicrobial drug development worldwide. Molecular hybridization is a well-established tool for developing multifunctional compounds to tackle drug resistance. Inspired by the antibacterial profiles of isatin and thymol, along with the efficiency of a triazole linker in molecular hybridization, herein, we report the design, synthesis and antibacterial activity of a novel series of triazole tethered thymol-isatin hybrids. Most of the hybrids exhibited a broad-spectrum antibacterial efficacy against standard human pathogenic as well as clinically isolated multidrug-resistant bacterial strains listed in the WHO's 'priority pathogen' list and also in the ESKAPE group. Among them, hybrid compound AS8 was the most effective against methicillin-resistant Staphylococcus aureus (MIC = 1.9 μM and MBC = 3.9 μM), exhibiting biofilm inhibitory potential. AS8 exhibited dehydrosqualene synthase (CrtM) inhibitory potential in MRSA and decreased the production of virulence factor staphyloxanthin, which is one of the key mechanisms of its anti-MRSA efficacy, which was further supported by molecular docking and simulation studies. Moreover, AS8 was found to be non-toxic and showed a potent in vivo antibacterial efficacy (90% survival at 10 mg kg −1 ) as well as a modulated immune response in the larva-based ( Galleria mellonella ) model of systemic infections. Overall findings confirmed that AS8 can be a promising candidate or take the lead in the treatment and further drug development against drug-resistant infectious diseases, especially against MRSA infections. Triazole-tethered isatin-thymol hybrids are developed for targeting multidrug-resistant bacterial strains with efficacy against MRSA acting via CrtM inhibition. The most active hybrid showed bactericidal and antibiofilm efficacy against MRSA and was capable of rescuing larvae from in vivo infection.</abstract><cop>England</cop><pub>Royal Society of Chemistry</pub><pmid>38283229</pmid><doi>10.1039/d3md00580a</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-3828-8110</orcidid><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid><orcidid>https://orcid.org/0000-0001-7474-7068</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2632-8682
ispartof MedChemComm, 2024-01, Vol.15 (1), p.234-253
issn 2632-8682
2040-2503
2632-8682
2040-2511
language eng
recordid cdi_pubmed_primary_38283229
source Royal Society of Chemistry
subjects Antibacterial activity
Antibacterial agents
Antimicrobial agents
Biocompatibility
Biofilms
Chemistry
Drug development
Drug resistance
Effectiveness
Hybridization
Hybrids
Immune response
Infectious diseases
Methicillin
Molecular docking
Multidrug resistance
Pharmacology
Public health
Staphylococcus infections
Thymol
Triazoles
Virulence factors
title The development of thymol-isatin hybrids as broad-spectrum antibacterial agents with potent anti-MRSA activity
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A05%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20development%20of%20thymol-isatin%20hybrids%20as%20broad-spectrum%20antibacterial%20agents%20with%20potent%20anti-MRSA%20activity&rft.jtitle=MedChemComm&rft.au=Singh,%20Atamjit&rft.date=2024-01-25&rft.volume=15&rft.issue=1&rft.spage=234&rft.epage=253&rft.pages=234-253&rft.issn=2632-8682&rft.eissn=2632-8682&rft_id=info:doi/10.1039/d3md00580a&rft_dat=%3Cproquest_pubme%3E2918142116%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c393t-16be8c2c31f655a0a001b1e00a21e296db1c296dae5a30e17c01e715d339af873%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2918142116&rft_id=info:pmid/38283229&rfr_iscdi=true